Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: A phase II trial using a triplet combination

Cancer

Volumn 103, Issue 3, 2005, Pages 569-575

  Leong, Swan Swan ^a   Wee, Joseph ^a   Tay, Miah Hiang ^a   Toh, Chee Keong ^a   Tan, Say Beng ^a   Thng, Choon Hua ^a   Foo, Kian Fong ^a   Lim, Wan Teck ^a   Tan, Terence ^a   Tan, Eng Huat ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Carboplatin; Chemotherapy; Gemcitabine; Nasopharyngeal carcinoma; Paclitaxel

Indexed keywords

CARBOPLATIN; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; GEMCITABINE; LAMIVUDINE; ONDANSETRON; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; HEPATITIS B; HUMAN; LETHARGY; MALE; METASTASIS; NASOPHARYNX CARCINOMA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SYNCOPE; THROMBOCYTOPENIA; TRANSAMINITIS; VIRUS REACTIVATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEUTROPENIA; PACLITAXEL; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 19944433612     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20804     Document Type: Article

References (36)

1. Al-Sarraf M, LeBlanc M, Giri PGS, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16:1310-1317.
2. Ong YK, Heng DM, Chung B, et al. Design of a prognostic index score for metastatic nasopharyngeal carcinoma. Eur J Cancer. 2003;39:1535-1541.
3. Merlano M, Vitale V, Rosso R, et al. Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med. 1992;327:1115-1121.
4. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiotherapy compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324:1685-1690.
5. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer Phase III trial. J Natl Cancer Inst. 1996;88:890-899.
6. Cheng SH, Tsai SY, Yen KL, et al. Concomitant radiotherapy and chemotherapy for early-stage nasopharyngeal carcinoma. J Clin Oncol 2000;18:2040-2045.
7. Chan AT, Teo PM, Leung TW, et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1995;33:569-577.
8. Au E, Ang PT. A Phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol. 1994;5:87-89.
9. Lin JC, Jan JS, Hsu CY. Outpatient weekly chemotherapy in patients with nasopharyngeal carcinoma and distant metastasis. Cancer. 1998;83:635-640.
10. Chi KH, Chang YC, Chan WK, et al. A Phase II study of carboplatin in nasopharyngeal carcinoma. Oncology. 1997;54:203-207.
11. Au E, Tan EH, Ang PT. Activity of paclitaxel by three-hour infusion in Asian patients with metastatic undifferentiated nasopharyngeal cancer. Ann Oncol. 1998;9:327-329.
12. Foo KF, Tan EH, Leong SS, et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol. 2002;13:150-156.
13. Tan EH, Khoo KS, Wee J, et al. Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol 1999;10:235-237.
14. Hainsworth JD, Burris HA, Erland JB, et al. Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced non-small cell lung carcinoma. Cancer. 1999;85:1269-1276.
15. Hansen SW. Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma. Semin Oncol 2002;29(Suppl 1):S17-S19.
16. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376.
17. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7:1748-1756.
18. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
19. Miller AB, Hoogstraten B, Staquet M. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
20. Tan SB, Machin D. Bayesian two-stage designs for Phase II clinical trials. Stat Med. 2002;21:1991-2012.
21. Newcombe RG, Altman DG. Proportions and their differences. In: Altman DG, Machin D, Bryant TN, et al., editors. Statistics with confidence, 2nd ed. London: BMJ Books, 2000:93-104.
22. Payers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 scoring manual, 3rd ed. Brussels: EORTC, 2001.
23. Decker DA, Drehchman A, Al-Sarraf M, Crissman J, Reed ML. Chemotherapy of nasophatyngeal carcinoma. A ten year experience. Cancer. 1983;52:602-605.
24. McCarthy JS, Tannock IF, Degendorfer P, Panzarella T, Furlan M, Siu LL. A Phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. Oral Oncol. 2002;38:686-690.
25. Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a Phase II toxicity, response, and survival analysis. J Clin Oncol. 1995;13:1860-1870.
26. Johnson DH, Paul DM, Hande KR, et al. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a Phase II trial. J Clin Oncol. 1996;14:2054-2060.
27. Glorieux P, Ortmanns P, Marien S, et al. Multi-center study of two dose levels of paclitaxel and carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC). Anticancer Res. 2001;21:1487-1494.
28. Hussain M, Vaishampayan U, Du W, Redman B, Smith DC. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol. 2001;19:2527-2533.
29. Mayerhofer K, Bodner-Adler B, Bodner K, Leodolter S, Kainz C. Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity. Anticancer Res. 2000;20:4047-4050.
30. 2 over 3 h) employed in the treatment of gynaecologic malignancies. J Cancer Res Clin Oncol. 2001;127:55-58.
31. Leong SS, Tan EH, Fong KM, et al. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable Stage III non-small-cell lung cancer. J Clin Oncol. 2003;21:1767-1774.
32. Cheong K, Li J, Karapetis CS. Gemcitabine and reactivation of hepatitis B. Med Oncol. 2003;20:385-388.
33. Zhong S, Yeo W, Schroder C, et al. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepatol. 2004;11:55-59.
34. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125:1742-1749.
35. Soh LT, Ang PT, Sng I, Chua EJ, Ong YW. Fulminant hepatic failure in non-Hodgkin lymphoma patients treated with chemotherapy. Eur J Cancer. 1992;28A:1338-1339.
36. Merican I, Guan R, Amarapuka D, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol. 2000;15:1356-1361.